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Introduction
Metalloproteinases play a significant role both in
physiological and pathological processes in the human
body, acting as mediators in remodelling and degrada-
tion of extracellular space components. Much attention
has been paid to their involvement in neoplasia, mech-
anisms of invasion and formation of metastases. An
increase in the level of metalloproteinases initiates
spread of cancer cells, thus causing tumor invasion and
formation of distant metastases [14]. It has been shown
that MMP-8 is secreted by squamous epithelial carci-
noma cells, MMP-7 is produced by cancer cells of the
stomach, breast and lungs, while MMP-2, MMP-9 and
MMP-14 by epithelial cells of various cancers [10].
Bramhall et al. [2] performed comparative analysis of
the expression of metalloproteinases (MMP-2, MMP-
3, MMP-7 and MMP-11) in pancreatic ductal carcino-
ma and healthy pancreas (intended for transplantation)
using Northern blot method and in situ hybridization
Their results clearly indicated an increase in the
expression of metalloproteinases in cancer specimens
as compared to healthy tissues. 
Matrix metalloproteinase 9 (MMP-9) is produced by
neoplastic cells as well as by host cells that form the
connective tissue stroma indispensable for tumor
growth. In neoplastic invasion, MMP-9, involved in
degradation and remodelling of the extracellular matrix,
and in breakdown of the basement membrane of vessels
and ducts, helps overcome the physical barriers and
contributes to the formation of distant metastases. It also
promotes tumor neovascularization. Numerous studies
have been conducted on its role in the devolopment of
carcinomas of the breast, the bladder, the pancreas, the
colon, the prostate or hypophysial adenomas [4]. A rela-
tionship has been described between MMP-9 activity
and tumor metastasis formation and patients' survival.
For instance, it has been demonstrated in patients with
advanced breast cancer that the higher the MMP-9
activity at the time of tumor diagnosis, the shorter over-
all survival [18]. Similarly, MMP-9 expression has been
found to be an unfavorable prognostic marker in non-
small cell lung cancer [17]. 
Therefore, the current study objective was to assess
the expression of MMP-9 in pancreatic ductal cancer,
and to analyse the correlation of MMP-9 with chosen
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anatomo-clinical parameters: age and gender, histological
type of cancer, grade of histological malignancy, lymph
node involvement and formation of distant metastases. 
Materials and methods
Material. The study involved a group of 36 pancreatic ductal car-
cinoma patients (8 men, 28 women; of them 17 aged <60 and 19
aged 60 or above) surgically treated at the Department of Gas-
troenterological Surgery, Medical University of Bia³ystok, in the
years 1999-2004. Hematoxylin-eosin -stained section were exam-
ined according to the TNM classification. Each tumor was sec-
tioned parallel to the longest axis and at least one total oblong-sec-
tion (2-3 mm thick) was obtained. It was then divided into small
blocks, 1-1.5 cm in diameter, to obtain 4-8 sections consisting of
tumor and adjacent macroscopically unchanged tissues. 
Immunohistochemistry. Immunohistochemical investigations
were performed using monoclonal antibody (Novocastra/NCL-
MMP-9/clone 2C3) directed against human matrix metallopro-
teinase 9. Slides of 4 μm-thick serial sections of the primary tumor
were prepared from each patient. A standard avidin-biotin
immunoperoxidase method (Novostain Super ABC Kit Universal)
was used for the detection of MMP-9. Briefly, the slides were
dewaxed using xylene, transferred to alcohol, placed in citric acid
buffer (pH=6.0) and heated in a microwave oven (700 W) for 10
min to expose antigens. Endogenous peroxidase activity was
blocked by incubating the sections in 3% hydrogen peroxide in
methanol for 10 min. The slides were then washed 3 times in phos-
phate-buffered saline (PBS) and incubated in normal horse serum
for 15 min to reduce nonspecific antibody binding. After washing
with PBS, the slides were incubated overnight at room temperature
with monoclonal antibody (Novocastra/NCL-MMP9/clone 2C3;
dilution 1:40, Biokom, Poland) was used. Nonspecific mouse IgG
was used as a negative control. The reaction products were visual-
ized with diaminobenzidine DAB (DAKO S3000, Dako, Poland). 
Evaluation of samples. Cytoplasmic immunostaining and poor
stromal immunostaining (Fig. 1 and 2) was observed. Expression
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Fig. 1. Expression of MMP-9 in cancer cells
(magn. × 40).
Fig. 2. Cytoplasmic expression of MMP-9
(magn. × 40).
was semi-quantitatively assessed in neoplastic cells of the primary
tumor and was defined as follows:
• negative - indicating lack of reaction to the presence of
MMP-9 or reaction in <30% of cells, 
• positive - reaction to MMP-9 visible in >30% of cells.
The percentage of MMP-9 positive cells was calculated in 500
cancer cells in each preparation, at a magnification of 400 x. The
results were subjected to statistical analysis using exact Fisher test and
χ2 test. The value p<0.05 was accepted as the level of significance.
Results and discussion
In recent years, literature reports have described the
relationship of the degradation of the extracellular
matrix, particularly of the basement membrane, as the
basic mechanism facilitating invasion and formation
of metastases by cancer cells. The extracellular matrix,
which consists of various types of collagens, laminin,
fibronectin, elastin and proteoglycans, is degraded by
proteinases, such as metalloproteinases. The expres-
sion of metalloproteinases is variously regulated and
correlates with invasiveness and formation of metas-
tases in carcinomas of the thyroid, the prostate, the
ovaries, the stomach and the lungs [16].
We analyzed the expression of matrix metallopro-
teinase-9 (MMP-9) in correlation with chosen anato-
mo-clinical parameters (Table 1). No statistically sig-
nificant relationship was found with age and gender of
the studied patients. 
The studied group of tumors consisted of adenocar-
cinoma-type and adenocarcinoma mucinosum neo-
plasms. The MMP-9 expression strongly correlated
with the presence of mucus, previously shown to facil-
itate cancer spread. Therefore, adenocarcinoma muci-
nosum is more aggressive than ordinary adenocarcino-
ma and more difficult to treat. However, no literature
data are available on the relationship between MMP-9
expression and secreting or non-secreting histological
type of carcinoma. Gress et al. [5] have noticed that
matrix metalloproteinase 9 can be associated with the
process that leads to strong desmoplastic reaction i.e.
proliferation of the connective tissue stroma compo-
nents observed in pancreatic carcinomas.
The role of matrix metalloproteinase 9 has been the
subject of many current studies revealing that MMP-9
expression in tumor correlates with shorter survival
time. Tumor size, lymph node involvement or distant
metastases significantly correlate with shorter survival
[7]. Moreover, MMP-9 has been found to contribute to
the aggressive behaviour of pancreatic carcinoma and
thus lies behind the poor prognosis [6].
In our study, the expression of matrix metallopro-
teinase 9 was observed in all patients with lymph node
involvement. Migration of cancer cells via the lymphat-
ic system plays an essential role in tumor invasion and
in the formation of metastases in lymph nodes. Degra-
dation of extracellular matrix by metalloproteinases is
the necessary prerequisite for cell migration. Migration
of cancer cells can be enhanced through MMP-9 over-
expression and is reduced through overexpression of
TIMP (tissue inhibitor of metalloproteinase) or applica-
tion of MMP-9 inhibitors [1,3]. Yamamoto et al. [19]
have confirmed that both cancer cells and stromal cells
are the major source of matrix metalloproteinase 9 in
pancreatic ductal carcinoma tissues (among 70 cases,
93% of carcinoma cells and 60% of stroma cells were
MMP-9 positive). However, MMP-9 expression was
insignificantly correlated with such pathological factors
as tumor size, lymph node involvement, formation of
distant metastases or tumor stage. Nevertheless, each
tumor shows different expression of metalloproteinase 9
and it is likely that MMP-9 differently affects invasive-
ness and formation of metastases of the respective
tumors. According to Maatt et al. [11], matrix metallo-
proteinase 9 does not have a special role in pancreatic
ductal carcinoma. The authors analyzed the expression
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Table 1. Expression of MMP-9 in pancreatic ductal adenocarcino-
ma in association with chosen anatomoclinical parameters
of MMP-9 in 8 cases of pancreatic tumor. The reaction
was pronounced only in tumor epithelial cells, but it was
negative in stromal cells in most cases (only sporadic
fibroblasts and endothelial cells were positive). Zucker et
al. [20] observed MMP-9 expression only in 19 out of 45
(43%) pancreatic ductal carcinomas but not in healthy
pancreas specimens (p=0.0009). Six of 19 (32%) pan-
creatic tumors showed either moderate or strong expres-
sion. No expression of MMP-9 was found in adjacent tis-
sues, stromal cells of the cancer or in the normal pan-
creas. No correlation was observed between MMP-9
expression with histological differentiation of the cancer,
tumor size, lymph node involvement or survival time. 
We found MMP-9 expression in all patients with dis-
tant metastases. Numerous reports seem to confirm that
matrix metalloproteinase 9 has a significant effect on
the formation of metastases of pancreatic ductal carci-
noma. Matsuyama et al. [12] have proved that pancreat-
ic ductal carcinomas with metastases show much high-
er MMP-9 expression than metastasis-free carcinomas.
Similarly, Nagakawa et al. [13], who analyzed 32 cases
of pancreatic ductal carcinoma, found distant metastases
in 31 of them and demonstrated a major role of matrix
metalloproteinase 9 in cancer cell infiltration of blood
vessels, which is a risk factor of tumor spread. Angio-
genesis, i.e. neovascularization, also plays an outstand-
ing role in the formation of distant metastases. It has
been shown that tumor without additional blood vessels
can reach 1-2 mm in diameter and needs nutrients sup-
plied by blood vessels to grow and proliferate. Angio-
genesis is strictly regulated by the system of stimulators
and inhibitors, starting with the release of proteases that
decompose the basement membrane and the extracellu-
lar matrix. Metalloproteinase 9 helps cancer cells pass
through the extracellular matrix barrier and participates
in the modulation of signals that affect cell transforma-
tion, growth factors, angiogenesis and apoptosis
[8,9,15]. The results of our study indicate a correlation
between the expression of MMP-9 in pancreatic ductal
carcinoma and worse prognosis (shown by lymph node
involvement and distant metastases). 
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